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Reciprocal copy-number variation (CNV) of a 593 kb region of 16p11.2 is a common genetic cause of autism spectrumdisorder (ASD), yet
it is not completely penetrant and can manifest in a wide array of phenotypes. To explore its molecular consequences, we performed
RNA sequencing of cerebral cortex from mouse models with CNV of the syntenic 7qF3 region and lymphoblast lines from 34 members
of 7 multiplex ASD-affected families harboring the 16p11.2 CNV. Expression of all genes in the CNV region correlated well with their
DNA copy number, with no evidence of dosage compensation. We observed effects on gene expression outside the CNV region,
including apparent positional effects in cis and in trans at genomic segments with evidence of physical interaction in Hi-C chromosome
conformation data. One of the most significant positional effects was telomeric to the 16p11.2 CNV and includes the previously
described ‘‘distal’’ 16p11.2 microdeletion. Overall, 16p11.2 CNV was associated with altered expression of genes and networks that
converge on multiple hypotheses of ASD pathogenesis, including synaptic function (e.g., NRXN1, NRXN3), chromatin modification
(e.g., CHD8, EHMT1, MECP2), transcriptional regulation (e.g., TCF4, SATB2), and intellectual disability (e.g., FMR1, CEP290). However,
there were differences between tissues and species, with the strongest effects being consistently within the CNV region itself. Our ana-
lyses suggest that through a combination of indirect regulatory effects and direct effects on nuclear architecture, alteration of 16p11.2
genes disrupts expression networks that involve other genes and pathways known to contribute to ASD, suggesting an overlap in mech-
anisms of pathogenesis.Introduction
Autism spectrum disorder (ASD) is a complex, heteroge-
neous developmental disorder affecting 1% of the popula-
tion.1 Although much of the genetic etiology remains
unexplained, the collective impact of copy-number varia-
tion (CNV), most of which involve genomic segments
that encompass many genes and regulatory elements,2,3
is substantial.4 The association between ASD and large,
recurrent, reciprocal CNVs, often as de novo variants, has
been highly significant and consistent across multiple
studies.5–7 Nonrecurrent CNVs (i.e., deletions and duplica-
tions that are not of identical size and location) can be
aligned by chromosomal position to define a minimum
region of overlap that can harbor a strong effect driver
of phenotypic outcomes (e.g., MBD5 [MIM 611472] in
2q23.1 deletion syndrome [MIM 156200]8–11 or EHMT1
[MIM 607001] in 9q34.3 deletion syndrome [MIM
610253]10,12,13). However, recurrent CNVs are predomi-
nantly due to nonallelic homologous recombination
(NAHR), mediated by flanking segmental duplica-
tions. The breakpoints of these NAHR-mediated events
are defined by the flanking repetitive sequences, and there-
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Previous CNV,5,7,14,15 exome-sequencing,4,16–18 and
balanced chromosomal abnormality (BCA)8,10 studies sug-
gest a substantial impact in ASD of loss-of-function muta-
tions that result in functional hemizygosity. However,
they have also highlighted the need for functional
genomic approaches to augment DNA-based studies. First,
despite clear evidence of a strong role for genes that regu-
late synaptic function (e.g., SHANK3 [MIM 606230],
NRXN1 [MIM 600565], GRIN2B [MIM 138252], NLGN4
[MIM 300427]19), recent studies have also identified
chromatin modifiers and transcriptional regulators as
significant ASD risk factors,10,17,18 some of which have
previously been implicated in a spectrum of psychiatric
disorders.10,20 These associated genes include global regu-
lators of gene expression as well as members of funda-
mental developmental pathways, such as b-catenin18
and FMRP signaling.16 Second, the genetic discoveries
and their associated effect sizes predict that there are
hundreds, if not thousands, of genes that confer risk
for ASD,7,18 suggesting a genetic architecture that
complicates any unified model of disease pathogenesis.
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pathways as significantly altered in ASD. Genes respon-
sible for neuronal development and immune response
have emerged as commonly dysregulated in several
studies,21,22 including one analysis of coexpression in
postmortem brain, which also found regional differences
implicating abnormal patterns of brain development.23
Finally, there is significant evidence that some genes
initially implicated in ASD through inactivating muta-
tions also confer increased risk through duplication,10
prompting the hypothesis of morbid genomic loci that
are sensitive to alterations in gene dosage, consistent
with microarray-based CNV studies.5,7,10,14,15,24
Among recurrent CNVs in ASD, a segment of 16p11.2
represents one of the most common etiological factors,
accounting for ~1% of all ASD cases.7,25 This 593 kb re-
gion contains 29 genes (25 of which are protein coding),
including transcription factors (e.g., MAZ [MIM 600999],
TBX6 [MIM 602427]) and chromatin modifiers (e.g.,
HIRIP3 [MIM 603365], INO80E [RefSeq NM_173618]), as
well as other genes with a wide array of cellular functions.
The region is flanked by parallel and highly homologous
(>99% similarity) segmental duplications, each spanning
147 kb and containing 12 genes (10 protein coding), which
are duplicated within each copy of the segment. Despite
the uniformity of NAHR-mediated breakpoints, this CNV
confers risk to diverse phenotypic outcomes, including
ASD, schizophrenia, bipolar disorder, seizures, obesity,
and numerous other neurological and anthropometric
traits,5–7,26 suggesting a role for modifying factors that
affect penetrance and expressivity.
Both deletion (MIM 611913) and duplication (MIM
614671) of 16p11.2 are associated with ASD risk,27 a
dosage phenomenon that has been explored in zebrafish
models. In one study, the importance of strict dosage bal-
ance for genes in the 16p11.2 CNV segment has been
demonstrated by systematic suppression and overexpres-
sion of the genes individually and in pair-wise interac-
tions. This revealed KCTD13 (MIM 608947) as a major
driver of mirrored neuroanatomical phenotypes and
detected significant interactions with MAPK3 (MIM
601795) and MVP (MIM 605088).28 In another zebrafish
study, loss of function for most 16p11.2 orthologs re-
sulted in changes in brain morphology, axonal density,
and motor response.29 Here, we have taken an alternative
strategy to investigate the effect of reciprocal dosage
change of this genomic segment, by using RNA
sequencing to assess dosage-dependent gene expression
differences in the cerebral cortex of mouse models of
duplication/deletion and in cell lines derived from multi-
plex ASD families with the CNV. Our results reveal an
impact of 16p11.2 CNV on transcription of all genes
within the region, as well as on a network of dysregulated
genes and pathways, including genes involved in synap-
tic function, chromatin modification, and known con-
tributors to ASD and intellectual disability, suggesting
convergence of 16p11.2 pathogenic mechanisms on
several common ASD pathways.The AmMaterial and Methods
Samples
We sequenced RNA from the cortical tissue of mice harboring dele-
tion and duplication of the 7qF3 region of synteny conservation
with 16p11.2 (n ¼ 16) and lymphoblastoid cell lines (LCLs)
derived from 34 individuals from seven, multiplex ASD families.
The mouse models were created at the Cold Spring Harbor Labora-
tory by A. Mills and colleagues, as previously described in Horev
et al.,30 and provided by the Jackson Laboratories (stock numbers
013128 and 013129). Sixteen mice were selected from two litters
of an engineered line with deletion or duplication of the mouse
16p11.2 equivalent region plus four additional genes found in
the human immediately outside of the segmental duplication,
centromeric to the CNV (Cd2bp2, Tbc1d10b, Mylpf, Sept1). Within
each litter, four mice with CNV were compared to four wild-type
littermates (eight total wild-type mice; Figure S1A available on-
line). The design was fully sex balanced for each genotype. LCLs
were obtained from the Autism Genome Resource Exchange
(AGRE), which has established a repository for biological material
from ASD-affected families supplemented with genotype and
phenotype information. The families were characterized as dele-
tion (four families) and duplication (three families) and included
multiple siblings that were both affected and unaffected (see
Figure S1B for family pedigrees). The study was approved by the
IRB of Partners Healthcare.RNA Sequencing
Dissection of mouse cortex was performed simultaneously for all
mice at 8 weeks of age. Both mouse cortex and human LCL
RNA-seq libraries were prepared with a customized version of the
originally published, strand-specific dUTP method.31–33 Human
RNA-seq was performed with two biological replicates (indepen-
dent cell pellets per definition of ENCODE project34) for each indi-
vidual. Each library also included 1 ml of a 1:10 dilution of ERCC
RNA Control Spike-Ins (Ambion) containing 92 synthetic RNA
standards of known concentration and sequence. These synthetic
RNAs cover a 106 range of concentration, as well as varying in
length and GC content to allow for validation of dose response
and the fidelity of the procedure in downstream analyses.35 See
Table S1 for complete molecular protocol. Libraries were multi-
plexed, pooled, and sequenced on multiple lanes of an Illumina
HiSeq2000, generating an average of 40M and 60M paired-end
50-cycle reads for each mouse sample and across both human
replicates, respectively.Sequence Analysis
Raw sequence data were quality checked with fastQC36 and
aligned with TopHat2 via default parameters against the RefSeq
transcriptome, mm10 for the mouse (UCSC Genome Browser, ac-
cessed September 2012), and hg19 for the human (UCSC Genome
Browser, accessed February 2013). All aligned reads were analyzed
with RNA-SeqQC37 to ensure uniformity of alignment rate, dupli-
cation rate, evenness of coverage, GC content, and rRNA content.
Reads aligned to the ERCC synthetic RNAs were used to check
the linearity of dose response within and between samples
(Figure S2A), to determine the abundance limits of gene expres-
sion that could be accurately quantified in our experiment
(defined as the average abundance of the lowest detectable
ERCC transcript from all samples; Figure S2B), and to assess the po-
wer to detect differential expression at varying fold-changes. Rawerican Journal of Human Genetics 94, 870–883, June 5, 2014 871
gene level counts were tabulated with the BEDTools suite38 against
the human and mouse RefSeq transcriptomes (both accessed
February 2013). Genes with read counts below our detection
threshold in any individual sample were excluded from analysis
in all samples, and raw counts were normalized with the total
number of counts generated per sample prior to statistical analysis.Differential Expression Analysis
Gene level read counts generated by RNA-seq are overdispersed
relative to the Poisson; therefore, we chose the negative binomial
distribution to model these data.39,40 The mouse cortex data were
analyzed with negative binomial generalized linear models
(GLMs). The dispersion parameter for each gene was estimated
with an iterative weighted least-squares approach for the GLM
analysis. For the human LCL data, negative binomial generalized
linear mixed models (GLMMs) were used, with random effects to
account for the correlations due to relatedness among individuals.
To fit a negative binomial GLMM, the Poisson-lognormal
approach was used. The covariance among individuals was based
on a relationship matrix estimated from the pedigree, which ac-
counts for similarity in expression based on the degree of shared
genetic background.
All analyses were conducted in R with the MASS41 package for
GLMs and pedigreeMM42 package for GLMMs. Empirical p values
were generated by permutation of expression values for a gene
over the individuals. Differential expression analysis was per-
formed to assess linear trends associated with reciprocal dosage
imbalance by regressing gene expression as a linear function of
16p11.2 (or 7qF3) copy state (reciprocal expression model). For ef-
fects specific to the direction of CNV, we also fit a factorial ANOVA
with genotype and sex as the factors for mouse, and genotype, sex,
and affected status as factors for the human LCLs (deletion- and
duplication-specific models). We used FDR corrected p values
(Benjamini-Hochberg FDR) for thresholds of statistical signifi-
cance and permutation to establish empirical p values in the hu-
man cohort. Permutation was not performed on the mouse data
due to insufficient degrees of freedom for randomization. Nomi-
nally significant results were retained for exploratory analyses.
See Appendix A for complete details.Network and Enrichment Analyses
To determine patterns of differential gene expression and coex-
pression networks as a consequence of 16p11.2 CNV, we per-
formed pathway and enrichment analyses utilizing orthogonal
approaches. First, we used weighted-gene coexpression network
analysis (WGCNA)43,44 to identify modules of coexpressed genes
among nominally significant differentially expressed loci in the
reciprocal expressionmodel. We also assessed the physical interac-
tions and networks of dysregulated genes by using DAPPLE.45
Next, we performed overrepresentation analysis to identify
enriched pathways with the BIOCARTA, KEGG,46,47 PANTHER,48
and REACTOME49 databases and statistically significant gene
ontology (GO) terms with DAVID,50 which are further summa-
rized by REVIGO.51We used all genes with expression levels above
our detection thresholds as the background list for both themouse
cortex (14,435 genes with human orthologs) and human LCLs
(13,812 genes that converged in our statistical analyses from the
reciprocal model, 14,133 genes that converged from the direc-
tion-specific contrasts). Enrichment for differentially expressed
genes by chromosomal location was performed by binning genes
by chromosome band and performing Fisher’s exact tests with872 The American Journal of Human Genetics 94, 870–883, June 5, 2Enrichr.52 Gene set enrichment analysis relied on ranking the
list of genes based on statistical significance with GSEA53 with
the default settings. Networks were visualized with Cytoscape
2.8.3/3.1.54 A false discovery rate (FDR) of 5% (q < 0.05) was
used to interpret statistical significance.Results
RNA-Seq of Human LCLs with 16p11.2 CNV and
Comparable Mouse Brain Tissue
We performed RNA sequencing on the cortical tissue of 8
mice with CNVof the 16p11.2 syntenic region (4 deletion,
4 duplication) and 8 wild-type littermates, as well as on 34
human LCLs from 7 multiplex autism-affected families
harboring 16p11.2 CNVs (4 deletion families, 3 duplica-
tion families) to determine the effects of altered 16p11.2
copy state on expression in cis and in trans. There were
10,992 genes expressed in both mouse cortex and human
LCLs at measurable abundance (based on the synthetic
RNA spike-ins, as defined in Methods), with an additional
4,974 genes expressed only in mouse cortex and 3,142
genes expressed only in human LCLs. Of the genes ex-
pressed in both tissues, the correlation in gene expression
was high (Spearman rank correlation [SRC] > 0.99)
between samples of the same tissue, but was predictably
lower between mouse cortex and human LCLs (SRC:
0.40–0.41; Figure S3). In mouse cortex, 29 of the 33 genes
in the region of manipulated dosage in 7qF3, which ex-
tends slightly beyond the region corresponding to the
16p11.2 CNV (see Methods), met detection thresholds.
In human LCLs, 21 of the 29 genes localized to the
16p11.2 segment met detection thresholds. We evaluated
expression of the 603 loci previously associated with
ASD as defined from the Simons Foundation55 and Au-
tismKB56 (accessed August 2013), revealing that at this
sequencing depth, we detected expression of 543 (90%)
of these genes in the mouse cortex and 364 (60%) of genes
in human LCLs.
Transcriptional Impact of 16p11.2 CNV on
Dosage-Altered Genes
When comparing the samples with deletion to their corre-
sponding diploid controls, we observed a relatively uni-
form reduction in gene expression both for human genes
in the 16p11.2 CNV in LCLs and for their mouse orthologs
in cerebral cortex (mean expression 5 standard devia-
tion ¼ 0.543 5 0.103 and 0.493 5 0.073, respectively)
(Figures 1A and 1B). Duplication resulted in a correspond-
ing, though slightly more variable, increase in expression
(1.443 5 0.123 and 1.533 5 0.143 in human LCLs
and in mouse cortex, respectively). Both findings indicate
that there is little or no dosage compensation involved
in the regulation of expression of any genes within the
CNV region. We refer to ‘‘reciprocal expression’’ herein to
represent genes that are linearly correlated with 16p11.2
dosage state, and genes are referred to as significant
in ‘‘reciprocal model’’ based on linear regression of gene014
Figure 1. Expression Changes of Genes within the 16p11.2 CNV
Region
Relative fold change in expression across (A) the 16p11.2 syntenic
region (7qF3) inmouse cortex with copy-number variation and (B)
the 16p11.2 CNV in human LCLs.Wild-type refers to familymem-
bers without CNV in (B). The CNV breakpoints in the engineered
mouse strain are represented by dashed vertical lines, whereas in
human, the breakpoints are found within the region’s flanking
segmental duplications, represented in orange. Deletion and
duplication result in relatively uniform gene expression patterns
with little evidence of dosage compensation. Expression estimates
are counts per million mapped reads, and each point represents
the relative ratio (fold change) in expression between wild-type
and an abnormal copy state. Note that one gene, Gdpd3, was
removed from (A) because of highly variable, sex-specific expres-
sion differences that we detected by RNA-seq and have been previ-
ously reported by Horev et al. as due to background differences in
parental mouse strains.30,57expression with copy state. In the mouse cortex, 25 of the
29 16p11.2 orthologs that met detection thresholds were
significant at an FDR q < 0.05, and in human LCLs 18 of
the 20 genes within the 16p11.2 CNV were significant at
the same FDR-corrected threshold. In the human CNV
region’s flanking segmental duplications, the average
gene expression compared to control was 0.763 for
deletion and 1.223 for duplication, consistent with the
respective 3:4 and 5:4 copy ratios of the genes in these seg-
ments. Only SULT1A3 (MIM 600641), SULT1A4 (RefSeq
NM_001017390), and LOC613037 (RefSeq NR_002555)
did not show consistent differential expression, as there
was a large variance for expression of these genes. No com-
parable analyses were performed in the mouse because the
segment is not duplicated in the mouse.
Genome-wide Effects of 16p11.2 CNV on Gene
Expression
We observed differences genome-wide in the expression of
genes as a consequence of the CNV dosage. In the mouse
cortex, when we considered the dosage effect by regression
on copy state (1, 2, or 3 copies of the CNV region), weThe Amfound that the strongest effect sizes across the genome
were detected within the CNV region itself (Figure 2A),
although two genes outside the region met FDR-corrected
significance thresholds (Kcnd3 and Slc7a14). Similar results
were observed in human LCLs, where the most significant
reciprocal dosage effects were within the 16p11.2 CNV
(Figure 2B). We next performed ANOVA, individually con-
trasting deletion and duplication of the CNV region to
wild-type animals or diploid humans. In the mouse cortex,
outside of the 7qF3 region, 36 genes were differentially ex-
pressed due to deletion and 6 genes were differentially ex-
pressed due to duplication at FDR-corrected thresholds,
with 2 genes significant at FDR thresholds in the human
LCLs (Table 1). Comparing the nominal results of each
model identified genotype-specific changes in gene expres-
sion: 56% of all differentially expressed genes in mouse
cortex were only significantly altered by deletion, and
32% of such genes were specifically altered by duplication.
By contrast, in the human LCLs the effects for 38% and
57% of differentially expressed genes were unique to dele-
tion and duplication, respectively, though the human ped-
igrees had greater power to detect the effects of duplication
in this model (4 deletion, 10 duplication, 20 controls)
whereas the mouse study was perfectly balanced (see Table
S3and Figure S4). Overall, these results indicate that the
strongest and most consistent reciprocal effects are on
expression of the genes directly altered by the 16p11.2
CNV but that there is a detectable impact of deletion,
duplication, or both beyond the region of dosage change.
Regional Effects of 16p11.2 CNV
Changes in expression of genes outside of the CNV region
could result from direct effects of structural changes in the
chromatin or from indirect effects of pathway perturbation
due to altered dosage of one or more CNV genes. To assess
the former possibility in immediate proximity to the CNV,
we analyzed genes within a range of intervals spanning
either side of the 16p11.2 CNV segment (1 Mb, 2.5 Mb,
and 5 Mb) for potential positional effects of the dosage
change on gene expression in cis across all statistical
models.We found that in themouse cortex, the region cor-
responding to the distal segment in the human CNV
(based on gene content) was enriched for differential
expression within 1 Mb (9 of 19 genes; p ¼ 0.031), 2.5
Mb (11 of 24 genes; p ¼ 0.023), and 5 Mb (18 of 43 genes;
p ¼ 0.013), although there was no enrichment for compa-
rable windows in the region corresponding to the segment
proximal to the human CNV (Table S2). Indeed, cis posi-
tional effects are readily observed for genes in closest prox-
imity to the CNV breakpoint in Figure 1A. The human LCL
results were remarkably consistent with the mouse find-
ings: distal to the CNV there was significant enrichment
of all three size bins (p ¼ 0.025, 0.029, and 0.040 at 1
Mb, 2.5 Mb, and 5 Mb distal to the CNV, respectively)
and none of the bins was significantly enriched proximal
to the CNV (Table S2). Notably, this region of consistent
positional effect telomeric to the 16p11.2 CNV in humanserican Journal of Human Genetics 94, 870–883, June 5, 2014 873
Figure 2. Genome-wide Distribution of
Reciprocal Alterations in Gene Expression
log10(p values) across the genome in (A)
mouse cortex and (B) human LCLs.
Genome-wide there are no regions of dif-
ferential expression as significant as the
genes found within 16p11.2 and 16p11.2
syntenic (7qF3 in mouse) regions. See
Table S3 for complete expression and sig-
nificance details.includes the previously described ‘‘distal’’ 16p11.2 micro-
deletion.58 To establish the genome-wide null distribution
for enrichment of differentially expressed genes within a
genomic segment, we performed the same enrichment
analysis for every sequential 1 Mb, 2.5 Mb, and 5 Mb re-
gion in the genome in human andmouse. The enrichment
observed in the genomic segments distal to the CNVwas in
the tail of the distribution of the enrichment p values for
every bin size in both human and mouse (>97th percen-
tile), whereas the proximal region fell between the 40th
and 50th percentiles of the same distributions (Figure S5).
We next evaluated whether genome-wide gene expres-
sion differences might reflect trans positional effects due
to a structural impact on chromatin and nuclear organiza-
tion. Physical alterations to nuclear positioning have been
previously observed due to translocation59 and copy-num-
ber variation.60 We used Enrichr52 to determine whether
any cytogenetic band other than 16p11.2 was enriched
for differentially expressed genes and detected a strong
regional effect in 6p22 (p ¼ 3.59 3 106), as well as in
1p21, 1p22, 8p22, 12q22, 12q24, and 19q13 (q < 0.05).
When we integrated these segments enriched for differen-
tially expressed genes with Hi-C data generated to assess
chromatin folding and packaging in the nucleus of human
lymphoblastoid cell lines (from the UMass Hi-C data
browser), we found evidence for physical interaction be-
tween 16p11.2 and each of 6p22, 12q24, and 19q13, the874 The American Journal of Human Genetics 94, 870–883, June 5, 2014strongest of which occurred with
6p22 (Figure 3). At the higher reso-
lution of the Hi-C data (1 Mb seg-
ments), we also see evidence of
physical interaction between the
distal 16p11.2 segments in which po-
sitional effects were detected in cis
and the canonical 16p11.2 CNV re-
gion. As mentioned above, this distal
region has previously been associ-
ated with another microdeletion
syndrome implicated in neurodeve-
lopmental disorders.58 The Hi-C data
also suggest correlation with the
16p11.2 proximal segments, though
this region was not enriched for
differential expression. In the mouse
data, several chromosome bands
were significantly enriched for differ-entially expressed genes (q < 0.05) including 16qB2
(3q29 syntenic region) and 13qD2.2 (5q31 syntenic re-
gion). Our findings suggest that microdeletion syndromes
may influence gene expression by direct positional effects
both in cis and in trans. Further studies are warranted on
othermicrodeletion syndromes or classes of structural vari-
ation to determine whether similar genome-wide posi-
tional effects from CNV or BCAs are predictable based on
physical interactions within the nucleus.
Transcriptional Impact of 16p11.2 CNVon Expression
of ASD-Associated Genes
Among 603 genes previously associated with ASD as anno-
tated by SFARI55 and AutismKB,61 543 had established
orthologs that were expressed at detectable levels in
mouse cortex, so we evaluated whether these were overrep-
resented in the set of differentially expressed genes. We
found that genes previously associated with ASD were
significantly enriched among all differentially expressed
genes (p ¼ 0.046), and particularly among genes that
were significant in the reciprocal models in which expres-
sion changed as linear function of 16p11.2 copy state
(p ¼ 0.006). There was also enrichment of ASD-associated
genes among differentially expressed genes in the human
LCLs (76 ASD-associated genes, enrichment p ¼ 0.022),
although only 364 genes were expressed in LCLs at our
detection thresholds. In contrast to the mouse, there was
Table 1. Differential Expression Counts and Enrichment for Altered Expression of ASD-Implicated Genes
Genes
Analyzed
Nominally Significant
Differentially
Expressed Genesa
FDR-Significant
Differentially
Expressed Genesb
Detected
Human
Orthologsc
Total
ASD Genes
Analyzedd
Nominally Significant
Differentially Expressed
ASD Genesa
Significance
of ASD Gene
Enrichmentd,e
Mouse reciprocal 15,966 1,079 25 14,435 540 51 0.0063
Mouse del 15,966 2,344 59 14,435 540 101 0.0041
Mouse dup 15,966 1,504 24 14,435 540 55 0.2506
Human reciprocal 13,812f 587 19 – 358 17 0.3098
Human del 14,133 908 10 – 362 29 0.0490
Human dup 14,133 1,290 5 – 362 43 0.0197
aUncorrected p value < 0.05.
bBenjamini-Hochberg FDR-corrected q < 0.05.
cOrthologs were retrieved from the Jackson Labs database.
d16p11.2 genes that have been individually implicated in ASD (SEZ6L, MAPK3, KCTD13) were excluded from the enrichment analysis.
ep value by Fisher’s Exact Test.
fSome genes were not included because the statistical model failed to converge.significant enrichment of ASD-associated genes whose
expression was altered by deletion or by duplication only
(p ¼ 0.049 and 0.020, respectively), but not among genes
that showed reciprocal alterations (p ¼ 0.310) (Table 1).
Of the ASD-associated genes outside the CNV region, 15
were altered in both human andmouse data sets, including
FMR1 (MIM 309550), the causal locus of Fragile X
Syndrome (MIM 300624). We also assessed the enrich-
ment of ASD-associated genes identified by whole-exome
sequencing as harboring de novo loss-of-function (LoF)
mutations, as defined in Willsley et al.62 The highest con-
fidence gene sets (harboring two or more de novo LoF mu-
tations in exome studies) contained only nine genes—
eight expressed in our mouse cortex and six expressed in
our LCLs—and was not significantly enriched. However,
an expanded set of 122 genes that had been disrupted at
least once showed enrichment among differentially ex-
pressed genes comparable to the overall ASD-associated
gene-set in mouse cortex (p ¼ 0.013, 0.0143, and 0.0057
for CNV, deletion-only, and duplication-only models).
Enrichment in LCLs was not significant, consistent with
the tissue-specific differences that we observed for many
of our analyses (109 of 122 genes expressed in mouse cor-
tex, 92 expressed in LCLs; Table S9).
Weighted Gene Coexpression Network Analysis
Mouse genes with nominally significant reciprocal expres-
sion changes were clustered into four modules based upon
correlated expression, independent of the direction of
change, by weighted gene coexpression network analysis
(WGCNA) (Table S4). The largest module (herein referred
to as the Mouse 16p11.2 module) contained 393 genes
including all of the 16p11.2 syntenic genes. Although
the 16p11.2 syntenic genes had the greatest absolute corre-
lation with the overall module expression profile (eigen-
gene), more of the genes in this module were negatively
correlated with dosage of the CNV region than were
positively correlated: 274 genes (70%) were upregulated
by deletion and downregulated by duplication. This wasThe Amconcordant with the analysis of individual copy states rela-
tive to wild-type (Figure 4A; see Tables S4 and S5 for com-
plete details of the mouse cortex WGCNA). In the human
LCLs, the genes that were differentially expressed in the
reciprocal model were included in WGCNA analyses and
clustered into four coexpression modules, one of which
contained 96 genes, including all but 4 of the 16p11.2
genes (hereafter the Human 16p11.2 module). This mod-
ule of 96 genes exhibited similar patterns of expression
to the Mouse 16p11.2 module in that the 16p11.2 genes
had the largest absolute correlations with the module
eigengene, and a greater proportion of the non-16p genes
again showed anticorrelated expression with the 16p11.2
copy state (63 of 96 genes, 66%). Notably, only the genes
within the CNV region were conserved between the
modules in mouse cortex and human LCLs (Figure 4B).
See Tables S6 and S7 for complete details of module expres-
sion trends and module membership in human LCLs,
respectively.
Pathway Analysis of Global Gene Expression Changes
Gene ontology and pathway analysis in the mouse cortex
found enrichment among differentially expressed genes
for terms corresponding to cellular adhesion, cadherin
signaling, Rho GTPase signaling, transcriptional regula-
tion, actin cytoskeleton organization, neuron differentia-
tion, axonogenesis, and axon guidance (q < 0.05;
Figure 5A). In the human LCLs, we found enrichment of
terms related to nucleosome assembly and chromatin orga-
nization, as well as cell cycle regulation andmRNA process-
ing (q < 0.05; Figure 5B).
We asked whether the genes showing altered expression
converge on common pathways. We performed enrich-
ment analysis on the union of all of the altered genes
that overlapped between data sets and found overrepre-
sentation of terms related to histone methylation,
mRNA processing, filament organization, and vitamin
metabolism (q < 0.05; Figure 5C, Table S8). Gene set
enrichment analysis on ranked gene lists found pathwayserican Journal of Human Genetics 94, 870–883, June 5, 2014 875
Figure 3. Positional Effects as a Conse-
quence of Physical Interactions
Scatterplot presents the –log10p values asso-
ciated with reciprocal expression changes
across 16p11.2 deletion, control, and
16p11.2 duplication for each gene along
the length of chromosome 6. The heat
mapbelow shows the reportedHi-C correla-
tion(blue, lowcorrelation; red,highcorrela-
tion) between each section of chromosome
6 (x axis of heatmap) and the 16p11.2
region (y axis of chr16; coordinates,
chr16:29,000,000–31,000,000). Note that
the enrichment of low p values for differen-
tial expression over the region of chromo-
some 6 (6p22) corresponds to the greatest
evidence for physical interaction with
16p11.2 (red arrow), suggesting altered
physical interactions. See Table S3 for com-
plete expression and significance details.involving Wnt signaling, cadherin signaling, nucleosome
assembly, and cell adhesion as significantly enriched (q <
0.05). Finally, we applied DAPPLE to the 981 human
orthologs that were significant in the reciprocal analysis
in the mouse cortex (i.e., showed linear dosage changes
that were correlated with the CNV), which revealed a
highly interconnected network of 273 nodes and 320
edges that included a greater number of ASD-associated
genes than expected by chance (enrichment of gene set
in the direct interaction network: p ¼ 0.006) but was
not significant for genes within the 16p11.2 segment
(6 genes, p ¼ 0.792; Figure 6). A similar analysis in human
LCLs on 587 genes that were nominally significant in the
reciprocal expression model revealed a network of direct
interactions with 145 nodes and 220 edges but was not en-
riched for 16p11.2 or ASD-associated genes (Figure 7, see
also Figures S5–S7 for complete network analyses). How-
ever, a subnetwork of genes with altered expression was
observed containing a set of histone genes implicated in
nucleosome assembly as well as HDAC4 (MIM 605314),
a gene previously implicated in ASD, whose gene product
interacts directly with that of MAPK3, a gene from the
16p11.2 CNV.Discussion
Our transcriptome sequencing of mouse models and fam-
ilies harboring dosage alterations of the 16p11.2 microde-
letion/microduplication syndrome provides insights into
the functional genomic consequences, both in the region
of dosage change and more broadly in the genome, of a
common CNV that is associated with a variety of human
disorders. In both mouse cortex and human LCLs, there
was no evidence for dosage compensation of genes within
this CNV segment. Few genes outside the CNV region
had expression changes that were as significant as those
dosage-driven effects on genes within the CNV.
In ASD studies, LCLs are often the only tissues available
for large-scale analyses. The effect sizes detected in this876 The American Journal of Human Genetics 94, 870–883, June 5, 2study are modest and, much like DNA-based association
designs in complex disorders, suggest that well-powered
cohorts will be necessary to comprehensively evaluate
the transcriptional architecture of this disorder. Therefore,
it is likely that the need for many subjects will limit most
studies to the examination of peripheral tissues. Although
we observed ASD-associated genes and pathways that can
be detected reliably in the LCLs, our analyses in the mouse
also revealed that neural tissue can provide additional
insight, particularly with respect to ASD-associated genes.
By example, when we compare our data to RNA-seq data
from iPS-derived neural progenitor cells (NPCs) in an inde-
pendent study (M.E.T., unpublished data), we also find
significantly more ASD-associated loci expressed in hu-
man NPCs than LCLs and a correlation structure that
is higher between mouse brain and human NPCs than be-
tween human NPCs and human LCLs. Given that 16p11.2
represents a genomic disorder that is associated with a
spectrum of developmental, psychiatric, and anthropo-
metric traits, a complementary approach using multiple
tissue types will represent the ideal strategy for under-
standing its functional consequences on gene expression.
Based on our data, this should include multiple human
iPS-derived neuronal cell types because the impact on
ASD-associated genes and their networks is likely to vary
between tissues.
RNA sequencing in both mouse cortex and human LCLs
supports the hypothesis that possible positional effects in
cis can extend beyond the site of the CNV. We find altered
gene expression in the proximity of dosage change in both
mouse and humans, the former of which is not flanked by
segmental duplications as is the NAHR-mediated human
CNV. This cis positional effect is evident over distances of
1 Mb, 2.5 Mb, and 5 Mb and is specific to genes in the hu-
man region distal to the CNV and likewise in its syntenic
counterpart in mouse. This effect was one of the most
consistent results between human LCLs and mouse cortex
and encompasses the site of the recurrent 220 kb deletion
previously annotated as the distal 16p11.2 microdele-
tion syndrome.58 Publicly available Hi-C data63 aimed at014
Figure 4. Weighted Gene Coexpression
Network Analysis
WGCNA was used to perform correlation
network analysis of the differentially ex-
pressed genes in human and mouse. Heat-
maps are shown for gene expression in the
(A) ‘‘Mouse 16p’’ module and (B) ‘‘Human
16p’’ module. Each column represents
the RNA-seq expression of a single gene
in the module, with red indicating low
expression and yellow indicating high
expression. The rows in (A) represent the
four deletion samples, four duplication
samples, and eight wild-type samples,
and rows in (B) represent four deletion
samples, ten duplication samples, and 20
control samples.detecting genome-wide chromosome interactions revealed
that this segment is one of the most correlated with the
canonical 16p11.2 CNV region (not surprising given their
proximity), suggesting that altered chromosome folding
may influence the cis regulation of gene expression.
Consistent with the findings of Luo et al.,64 we did not
find evidence for a correlation between the extent or direc-
tion of altered expression and distance from the CNV for
the cis effects observed.
Outside of 16p11.2, we identified other contiguous
genomic segments with more differentially expressed
genes than would be expected by chance. The most signif-
icant of these was 6p22, for which the Hi-C suggested a
correlation with 16p11.2. This suggests that microdeletion
syndromes may influence gene expression both locally
and remotely by changing chromatin folding, thereby
altering physical interactions between chromosome re-
gions in the nucleus. Collectively, these data suggest that
positional effects from structural variation may have a sig-
nificant functional impact on gene expression, either as a
consequence of altering dosage of regulatory elements in
cis or from alterations to nuclear structure of the chromo-
somes. Our association-based approach cannot definitively
distinguish between direct positional effects and indirect
regulatory consequences of altered pathways, and these
data warrant extensive analyses across the spectrum of
structural variation.
The altered expression of genes previously associated
with ASD provides intriguing evidence for convergence
on common pathways from disparate mutational mecha-
nisms, such as CNV, translocation, inversion, and inacti-
vating point mutations in the coding sequence. Alteration
to gene expression in these pathways as a consequence of
16p11.2 dosage change potentially connects divergent hy-
potheses of ASD pathogenesis. Previous studies of hemizy-
gous disruption have revealed genes associated with ASD
and other abnormal neurodevelopment that are involvedThe American Journal of Humain critical neuronal functions, such
as synaptic transmission and cell-cell
interaction (e.g., GRIN2B, KIRREL3[MIM 607761], NRXN1). However, they have also revealed
genes involved in chromatin modification, methylation,
and transcriptional regulation (e.g., CHD8 [MIM 610528],
TCF4 [MIM 602272], FOXP1 [MIM 605515], EHMT1,
MBD5, SATB2 [MIM 608148], ZBTB20 [MIM 606025]), sup-
porting a model of ASD pathogenesis in which disruption
of neurodevelopment can be triggered by genes with
global effects on the expression of other genes. Here, we
find an interesting convergence between these two hy-
potheses in the pathways whose expression is altered by
16p11.2 CNV, which include genes that function at the
synapse (e.g., NRXN1, NRXN3 [MIM 600567], etc.), chro-
matin modifiers and transcription factors (e.g., CHD8,
EHMT1, SOX5, SATB2, FOXP1), and genes involved in
known causes of intellectual disability such as FMR1 and
CEP290 (MIM 610142). Although our gene-set enrichment
analyses clearly indicate that the effects of dosage change
at 16p11.2 include altered expression of some ASD-associ-
ated genes, individually most of these genes were detected
at nominal significance that do not survive stringent
correction thresholds. Our findings therefore warrant
validation inmuch larger samples and relevant neurodeve-
lopmental cell types, particularly because these data also
revealed substantial enrichment for pathways previously
implicated in ASD (e.g., cell adhesion, cadherin signaling,
WNT signaling pathway, axon guidance, mTOR signaling,
circadian rhythms).
In conclusion, CNV of 16p11.2 (or its equivalent
segment in the mouse) results in strong, consistent effects
on the expression of all genes within the CNV region and
in altered expression of many genes outside the CNV,
albeit at lower magnitude and statistical significance. Our
data indicate that the altered expression of genes not
located within the region of dosage change may be a
consequence of multiple mechanisms: direct positional
effects in cis; direct positional effects in trans by altering
physical interactions among chromosomes; and/orn Genetics 94, 870–883, June 5, 2014 877
Figure 5. Pathway Analysis of Differen-
tially Expressed Genes
Ontology enrichment analysis was per-
formed with DAVID. The uncorrected
–log10 p value of selected pathway en-
richments significant at FDR q < 0.05
are presented above for genes with recip-
rocally altered expression in (A) mouse
cortex, (B) human LCLs, and (C) both
mouse cortex and human LCLs, with
a full listing of pathway enrichments
found in Table S8. No FDR-corrected
significant terms emerged from the
mouse-human duplication intersection
gene set.indirect effects of altered pathways. Among the genes
showing marked differential expression as a function of
16p11.2 copy number, there is significant enrichment for
genes previously associated with ASD, indicating that
16p11.2 dosage could exert its influence on risk through
critical pathways that are already known to play major
roles in neurodevelopment and ASD. Consistent with
DNA-based studies of common complex disorders, our
data indicate that the effect sizes for alterations in gene
expression associated with this genomic variation are rela-
tively modest, yet capable of contributing to abnormal
neurodevelopment. These data also suggest that carefully
designed, large-scale transcriptome studies across multiple
tissues and cell types hold great promise in elucidating the
multiple contributing pathways that drive the pathogenic
process in ASD.Appendix A: Statistical Analysis of Differential
Expression
Modeling Approaches
We used two different approaches to model gene expres-
sion as a function of the deletion or duplication. The first
approach (hereafter referred to as reciprocal-Effect) consists
of fitting a linear model regressing gene expression as a
function of the number of gene copies within an individ-
ual. Based upon their genotype, individuals were scored
as follows: 0 for wild-type or control (WT), 1 for deletion
(Del), and 1 for duplication (Dup). The reciprocal-Effect
approach provides a measure for assessing gene expres-
sion profiles for linear trends associated with deletion/
duplication.878 The American Journal of Human Genetics 94, 870–883, June 5, 2014The second approach (hereafter
referred to as aov-Effect) was to fit a
factorial ANOVA with genotype and
sex as factors. The model included
both main effects and an interac-
tion term. Pairwise differences be-
tween means and linear combina-
tions of model parameters were
used to evaluate the specific hypoth-esis of interest. All the analyses were carried out in an R
environment.
Differential Expression Analysis of Mouse Data
To quantify gene expression, the counts of reads that map
to the transcribed regions in the genome (based upon
gene annotations from RefSeq65) are tabulated. The counts
were generated with BEDTools38 using options compatible
with the strand-specific sequencing library construction
method used.
Differential expression of genes across samples for
the count data was performed by generalized linear
models (GLMs), a general statistical framework for count
data.39,66,67 The distribution of counts arising from RNA-
seq is assumed to follow a Poisson distribution when only
technical variation is present and extensions to the Poisson
model are necessary to account for biological variation. The
negative binomial distribution is an extension of the Pois-
son that allows for overdispersion (greater variance) than
a Poisson model, for which the variance is equal to the
mean, and is recommended for RNA-seq analysis.64,68,69
The negative binomial can be formulated as a mixture of
Poisson distributions in which the mixing distribution is
Gamma
Y jE  PoissonðmEÞ : E  rðqÞ:
where the marginal distribution of Y is
EðYÞ ¼ m and VarðYÞ ¼ mþ m
2
q
If q is known, then the estimation falls within the GLM
framework and can be fit in R using the glm function
Figure 6. Protein-Protein Interaction
Network of Differentially Expressed
Genes in Mouse Cortex
DAPPLEwas used to generate a direct inter-
actome for the protein products from 981
human orthologs of genes (including 54
genes previously implicated in ASD) that
were differentially expressed in the mouse
cortex due to CNVof the 16p11.2 syntenic
region by the reciprocal expression model.
A cluster of 190 proteins includes 6 gene
products encoded in the 16p11.2 syntenic
region (red) as well as 24 genes previously
implicated in ASD (blue). The network re-
vealed a statistically significant enrich-
ment of ASD-associated genes (Fisher’s
exact test; p¼ 0.032), but not 16p11.2 syn-
tenic CNV genes (p ¼ 0.792).and the family ¼ negative.binomial(theta) option. q can
also be estimated with the glm.nb function from the
MASS package, using an iterative weighted least-squares
approach and fixing the dispersion viz. VðyÞ ¼ 1.41
For the reciprocal-Effect analysis, the model included
CNV, sex, and the interaction CNV:sex as fixed effects. In
addition, an offset variable containing the total counts
over all genes for each sample was used to compensate
for varying depth of sequencing across samples.
We fit the gene-by-gene models as follows:
d Estimate q for each gene with glm.nb and get the MLE
estimate.
d Assume q known and using glm fit a negative bino-
mial model.
d The fixed effects for each gene in the reciprocal-
Effects model genotype, sex, and their interaction.
d The fixed effects for each gene in the aov-Effects
model genotype, sex, and their interaction.Differential Expression Analysis of Human Data
As previously mentioned for the mouse analysis, normal-
ized counts were used as a measure of gene expression
and two modeling approaches were utilized in analyzing
the human data.
For reciprocal-Effect, a regression approach fitting gene
expression (e.g., normalized counts) as a linear function
of the number of copies of 16p11.2 regions within an indi-
vidual, as described above. The reciprocal-Effect approach
assesses gene expression profiles for linear trends associ-
ated with deletion/duplication. Because of the unequal
number of observations across genotypes either by status
or by sex in our family cohort, status-specific and sex-spe-
cific slopes and the three-way interactions were not fit. The
null expectation is that gene expression is similar across all
samples and therefore a common intercept was assumed
for all samples.The AmFor aov-Effect, a factorial ANOVA type approach was fit
with genotype, sex, and status as factors. Because all factor
level combinations were not present, a cell-means model
for the fixed effects was used wherein each combination
of genotype 3 sex 3 status was treated as an individual
level and inferences for any specific factors were based on
deriving contrasts.
Empirical p values were calculated for both approaches
by permuting the normalized expression values (pheno-
types) for a gene, across individuals, and refitting the
model every time for that gene. Using a two-sided testing
approach and taking the absolute value, the t statistics
for the slope or the contrasts were used as the permutation
test statistic and the empirical p values were estimated as
the number of times the permutation t statistic exceeded
the original t statistic. To determine the number of permu-
tations for each, we used the p values from fitting the
model as a guideline for a maximum of 106 runs for any
given set. Specifically, we used the integer ceiling of
(log10(p value)þ1) raised to the power 10.Random Effects
The R package pedigreeMM42 was used for fitting both the
reciprocal-Effect and the aov-Effect models. This package is
a wrapper around the standard mixed model package
lme4, which can be used to fit both linear mixed models
(LMMs) and generalized linear mixed models (GLMMs).
A GLMM approach was used with the fixed effects struc-
ture as mentioned above. Because there is currently no
simple approach to fit a negative binomial GLMM in R
with a relationship matrix included, a modification of
the Poisson GLMM, the Poisson-lognormal approach,
was used. The random effects structure employed was
ð1 j indlabÞ þ ð1 j obsIdÞ;
where the indlab effect is the effect of the covariance
among individuals based on the relationship matrixerican Journal of Human Genetics 94, 870–883, June 5, 2014 879
Figure 7. Interconnected Network of
Genes Differentially Expressed because
of 16p11.2 CNV
DAPPLE was used to generate a direct inter-
actome of the proteins encoded by 587
human genes that were differentially ex-
pressed from the reciprocal model in hu-
man LCLs. A cluster of 73 proteins includes
1 encoded in the 16p11.2 CNV region (red)
as well as 2 previously implicated in ASD
(blue). The highlighted box shows proteins
encoded by a subset of the differentially ex-
pressed genes in 6p22 that are involved in
nucleosome assembly and interact indi-
rectly with MAPK3, encoded by a 16p11.2
gene, through HDAC4.estimated from the pedigree, accounting for similarity in
expression due to shared genetic background. For example,
the relationship matrix for a nuclear family A consisting of
two parents and their two children would look like:
The obsId effect fits an individual-level random effects for
each observation.70 This is equivalent to fitting a negative
binomial model because marginally the variance is a
quadratic function of the mean.67Supplemental Data
Supplemental Data include seven figures and nine tables and can
be found with this article online at http://dx.doi.org/10.1016/j.
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